PSC
VNDA icon

Piper Sandler & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

Piper Sandler & Co’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-30,000
Closed -$338K – 70
2015
Q3 		$338K Buy
+30,000
New +$367K 0.36% 33
2014
Q4 		– Sell
-1,000
Closed -$10K – 163
2014
Q3 		$10K Sell
1,000
-1,000
-50% -$13.1K 0.01% 124
2014
Q2 		$32K Buy
+2,000
New +$26.6K 0.02% 105

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Piper Sandler & Co's VNDA Position: Q4 2015 in Review

Piper Sandler & Co sold out of Vanda Pharmaceuticals (VNDA) in Q4 2015, closing a stake of 30,000 shares — an estimated $338K sold.

Piper Sandler & Co first reported a position in VNDA in Q2 2014 and held it in 3 quarters. The position peaked at $338K in Q3 2015. 117 funds tracked by Wall St. Rank hold VNDA as of Q4 2015.

  • Piper Sandler & Co reported no remaining Vanda Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 30,000 Vanda Pharmaceuticals shares in Q4 2015, an estimated $338K.
  • Piper Sandler & Co first reported a position in Vanda Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Piper Sandler & Co's Vanda Pharmaceuticals position peaked at $338K in Q3 2015.
  • 117 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2015.

Based on Piper Sandler & Co's 13F filing for Q4 2015, filed 16 Feb 2016.